Answers are grounded in this paper and cite their sources.
Sovereignty in AI is usually framed as ownership: who owns the model, who owns the data, who owns the compute. Safety in AI is usually framed as constraint: how much harm can be statistically bounded, how fast can the kill switch be pulled. Both framings are wrong, and they are wrong for the same reason. A sovereign system is one whose behavior can be declared and verified. A safe system isone whose behavior can be proven not to contain an unsafe action within its envelope. Both require the same thing: a finite, enumerable, provable behavior set. An unbounded architecture has neither. It can be owned, but it cannot be sovereign over itself, because it cannot declare its own behavior. It can be statistically constrained, but it cannot be proven safe, because its behavior set is not enumerable. This paper states the claim plainly: sovereignty and safety are possible — not as aspirations,not as statistical constraints, but as specifications — because a bounded architecture has a behavior set that can be declared, verified, and certified, and an unbounded architecture does not. The paper states what sovereignty is not (possession without specification), what safety is not (statistical constraint), why the two are the same requirement, and what architecture supplies both. It cites the corpus that specifies the architecture and the two concrete cases that instantiate it. It names the trust root — the human signers on which the certificate's authority rests — and does not pretend to have solved it. It states the residual that every honest standard must state: the specification is on the record; the deployment is not. Attractive is not adopted.Status is stated in the abstract rather than the residuals: the architecture is specified (Layer1 complete), the TLA+ modules are written but not yet model-checked (Layer 2), andhardware validation has not started (Layer 3). The paper states what is possible; it does notclaim what is deployed.
No takes yet. Share an insight, caveat, or question.
TAALABI et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: